Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
October 31, 2024 3:23 PM 5 min read

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

by Chris Katje Benzinga Staff Writer
Follow

ArticleFeaturedTickersList12345!!!

Ark Funds, led by Cathie Wood, is one of the most well-known fund managers thanks to its actively managed ETFs that focus on future growth areas of innovation.

Two of the fund's ETFs celebrate their 10th anniversaries on Thursday. Here's a look back at the funds' launch and how they've performed over the last 10 years.

Ark Innovation: Wood and Ark Funds launched the Ark Innovation ETF (NYSE:ARKK) on Oct. 31, 2014. The fund has grown to become the most well-known and largest of the company's funds, with $5.78 billion in assets under management.

"ARRK is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily in domestic and foreign equity securities of companies that are relevant to the Fund's investment theme of disruptive innovation," the company's website says.

Disruptive innovation themes include autonomous mobility, precision therapies, next gen cloud, neural networks, intelligent devices, digital wallets, digital assets, smart contracts and multiomic technologies, according to the company.

"ARK defines ‘disruptive innovation' as the introduction of a technologically enabled new product or service that potentially challenges the way the world works."

Here are the current top 10 holdings in the ARKK ETF and their percent of net assets:

  1. Tesla Inc (NASDAQ:TSLA): 14.1%
  2. Roku Inc (NASDAQ:ROKU): 10.8%
  3. Coinbase Global (NASDAQ:COIN): 8.1%
  4. Roblox Corporation (NYSE:RBLX): 6.2%
  5. Palantir Technologies (NYSE:PLTR): 5.1%
  6. Robinhood Markets (NASDAQ:HOOD): 5.0%
  7. Block Inc (NYSE:SQ): 4.9%
  8. CRISPR Therapeutics (NASDAQ:CRSP): 4.5%
  9. Shopify Inc (NYSE:SHOP): 3.9%
  10. UiPath Inc (NYSE:PATH): 2.9%

Since the fund's inception, the ETF is up 161.4%. This return trails the current 10-year return of the SPDR S&P 500 ETF Trust (NYSE:SPY), which tracks the S&P 500.

Here's a look at how the returns of ARKK stack up against SPY, which is the oldest and largest U.S. ETF, over time:

Average Annual ReturnsARKKSPY
1-Year+19.9%+36.2%
3-Year-24.3%+11.8%
5-Year+2.6% +15.8%
Since ARKK Inception 10/31/14+10.2%+13.2%

The chart below from Benzinga Pro shows the 10-year return of ARKK.

For comparison, here is the 10-year chart of the SPY.

Read Next: EXCLUSIVE: Cathie Wood Tells Benzinga Why Tesla Should Trade As A Tech Stock

ARK Genomic: The Ark Genomic Revolution ETF (BATS:ARKG) was also launched by Ark Funds on Oct. 31, 2014. The fund currently has $1.33 billion in assets under management.

Themes for the genomics ETF include precision therapies, multiomic technologies, programmable biology, neural networks, next gen cloud and adaptive robotics, according to the company.

Here are the current top 10 holdings in the ARKG ETF and their percent of net assets:

Since the fund's inception, the ETF is up 38.9%. This return trails the current 10-year return of the SPDR S&P 500 ETF Trust.

Here's a look at how the returns of ARKG stack up against SPY over time.  

Average Annual ReturnsARKGSPY
1-Year-7.9% +36.2%
3-Year-29.9%+11.8%
5-Year-1.9% +15.8%
Since ARKG inception 10/31/14+3.3%+13.2%

Here is the 10-year chart of ARKG.

Why It's Important: The charts above show that ARKK and ARKG both experiences several years of strong growth and returns for investors, but have underperformed the broader S&P 500 market index in recent years.

The ETFs were once among the most talked about funds, and the company’s daily trading activity often moved stocks higher, given Wood's outperformance years ago.

While the S&P 500 ETF rebalances quarterly, the actively managed funds complete trades almost every day. Often, the average cost of shares rises over time for stocks that are going up, potentially hurting the gains.

Ark Funds typically invests in companies that it believes will have strong growth over the next five to ten years, which means the funds’ returns can sometimes take years to pay off.

Wood has been early to many themes, including buying shares of NVIDIA Corporation for around $5 in 2014, before the most recent stock split. The fund later sold out of its position in late 2022 and early 2023 and missed out on huge gains over the last nearly two years.

Getting the Tesla prediction right helped elevate Wood's status as a fund manager and led to increased interest in the Ark Funds ETFs.

Although interest in Ark Funds ETFs may have cooled in recent years, many investors still recall their impact and continue to track daily trading activity, watching closely which stocks Wood selects to hold for the next five to 10 years.

Read Next:

  • EXCLUSIVE: Why Does Cathie Wood Think Bitcoin Is Going To $1 Million — What Does She Know That We Don’t?

Image courtesy of Ark Invest and Shutterstock.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Broad U.S. Equity ETFsEducationSpecialty ETFsTop StoriesTechETFsArk FundsCathie WoodPro ProjectS&P 500Stories That Matter
ARKK Logo
ARKKARK Innovation ETF
$70.550.20%
Overview
ADPT Logo
ADPTAdaptive Biotechnologies Corp
$15.70-0.44%
ARKG Logo
ARKGARK Genomic Revolution ETF
$28.75-0.14%
CDNA Logo
CDNACareDx Inc
$19.47-%
COIN Logo
COINCoinbase Global Inc
$165.800.41%
CRSP Logo
CRSPCRISPR Therapeutics AG
$48.790.10%
HOOD Logo
HOODRobinhood Markets Inc
$84.401.91%
IONS Logo
IONSIonis Pharmaceuticals Inc
$86.730.27%
NRIX Logo
NRIXNurix Therapeutics Inc
$16.85-%
NTRA Logo
NTRANatera Inc
$202.00-0.51%
PATH Logo
PATHUiPath Inc
$12.980.70%
PLTR Logo
PLTRPalantir Technologies Inc
$137.651.29%
RBLX Logo
RBLXRoblox Corp
$66.710.44%
ROKU Logo
ROKURoku Inc
$86.080.27%
RXRX Logo
RXRXRecursion Pharmaceuticals Inc
$3.98-%
SHOP Logo
SHOPShopify Inc
$112.290.21%
SPY Logo
SPYState Street SPDR S&P 500 ETF Trust
$690.62-%
TSLA Logo
TSLATesla Inc
$411.780.16%
TWST Logo
TWSTTwist Bioscience Corp
$48.65-1.20%
TXG Logo
TXG10x Genomics Inc
$19.203.17%

"ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy, and consumer discretionary, that are relevant to the Fund's investment theme of the genomics revolution," the company's website says.

  1. Twist Biosciences (NASDAQ:TWST): 8.7%
  2. Recursion Pharmaceuticals (NASDAQ:RXRX): 7.0%
  3. CRISPR Therapeutics: 7.0%
  4. CareDx (NASDAQ:CDNA): 5.1%
  5. Adaptive Biotechnologies (NASDAQ:ADPT): 4.7%
  6. Veracyte Inc (NASDAQ:VYCT): 4.6%
  7. Ionis Pharmaceuticals (NASDAQ:IONS): 4.3%
  8. Nurix Therapeutics (NASDAQ:NRIX): 4.1%
  9. Natera Inc (NASDAQ:NTRA): 3.8%
  10. 10x Genomics (NASDAQ:TXG): 3.8%

The fund manager was also early in the Tesla growth story, predicting a $4,000 price target for the electric vehicle company back in February 2018. While Wood was laughed at for the price prediction at the time, the stock would hit the target on a split-adjusted basis in January 2021.

ARKK Logo
ARKKARK Innovation ETF
$70.550.20%
Overview
ADPT Logo
ADPTAdaptive Biotechnologies Corp
$15.70-0.44%
ARKG Logo
ARKGARK Genomic Revolution ETF
$28.75-0.14%
CDNA Logo
CDNACareDx Inc
$19.47-%
COIN Logo
COINCoinbase Global Inc
$165.800.41%
CRSP Logo
CRSPCRISPR Therapeutics AG
$48.790.10%
HOOD Logo
HOODRobinhood Markets Inc
$84.401.91%
IONS Logo
IONSIonis Pharmaceuticals Inc
$86.730.27%
NRIX Logo
NRIXNurix Therapeutics Inc
$16.85-%
NTRA Logo
NTRANatera Inc
$202.00-0.51%
PATH Logo
PATHUiPath Inc
$12.980.70%
PLTR Logo
PLTRPalantir Technologies Inc
$137.651.29%
RBLX Logo
RBLXRoblox Corp
$66.710.44%
ROKU Logo
ROKURoku Inc
$86.080.27%
RXRX Logo
RXRXRecursion Pharmaceuticals Inc
$3.98-%
SHOP Logo
SHOPShopify Inc
$112.290.21%
SPY Logo
SPYState Street SPDR S&P 500 ETF Trust
$690.62-%
TSLA Logo
TSLATesla Inc
$411.780.16%
TWST Logo
TWSTTwist Bioscience Corp
$48.65-1.20%
TXG Logo
TXG10x Genomics Inc
$19.203.17%
Comments
Loading...